The British National Formulary for Children is the unrivalled guidance on prescribing, dispensing and administering medicines to children.
BNF for Children is the only child-focused drug formulary in the world that is both independent, and has rigorous, accredited content creation processes. It is trusted by health professionals worldwide as their primary source for minimising medication errors in paediatrics.
SubscribeContent Updates
Speed and safety: Provides rapid reference to essential information on the selection of safe and effective medicines for individual patients
Evidence Grading: As part of NICE accreditation recommendations, BNFc content is now evidence graded to reflect the strength of evidence behind them, increasing transparency to support healthcare professionals with clinical decision making
Always up-to-date: The content is revalidated, revised, and updated on a monthly basis, making sure you access only the very latest prescribing knowledge
Worldwide credibility: The BNFc uses clinical evidence from a diverse range of sources and a network of experts, giving you the confidence to select medicines safely
*based on average data in the last 12 months
This update contains 3 significant changes, 5 dose changes and 1 new preparation.
Significant Changes:
• Benzodiazepines: reminder of risk of potentially fatal respiratory depression [MHRA/CHM advice] (advice in alprazolam, chlordiazepoxide hydrochloride, clobazam, clonazepam, diazepam, flurazepam, loprazolam, lorazepam, lormetazepam, midazolam, nitrazepam, oxazepam, temazepam; see example in diazepam).
• COVID-19: new guidance incorporating a collection of resources.
• Opioids: reminder of risk of potentially fatal respiratory depression [MHRA/CHM advice] (advice in alfentanil, buprenorphine, codeine phosphate, diamorphine hydrochloride, dihydrocodeine tartrate, dipipanone hydrochloride, fentanyl, hydromorphone hydrochloride, meptazinol, methadone hydrochloride, morphine, oxycodone hydrochloride, pentazocine, pethidine hydrochloride, remifentanil, sufentanil, tapentadol, tramadol hydrochloride; see example in morphine).
Dose Changes:
• Betamethasone with clioquinol [updated child age range].
• Digoxin [clarification of maximum doses for children 5-9 years].
• Glucagon [update to age ranges for hypoglycaemia].
• Idursulfase [updated age range].
• Sodium fluoride [updating dosing for prophylaxis of dental caries].
New Preparations: Cytotect® [cytomegalovirus immunoglobulin].
For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes
This update contains 4 significant changes, 5 dose changes and 2 new preparations.
Significant Changes:
• Adrenaline/epinephrine (Emerade®) pre-filled auto-injector: update on failure to activate [MHRA/CHM advice].
• Antimicrobial stewardship: new guidance.
• Etonogestrel (Nexplanon®) contraceptive implants: new insertion site to reduce rare risk of neurovascular injury and implant migration [MHRA/CHM advice].
• Medicines optimisation: new guidance.
Dose Changes:
• Benzoin tincture, compound [updated child age range].
• Eucalyptus with menthol [frequency of dosing].
• Eucalyptus with menthol [updated child age range].
• Fluocinolone acetonide with clioquinol [updated dosing frequency].
• Paracetamol with buclizine hydrochloride and codeine phosphate [child age ranges].
New Preparations:
Benzathine benzylpenicillin, Mozobil® [ plerixafor ].
For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes
This update contains 11 significant changes and 1 new preparation.
Significant Changes:
• Cannabidiol with clobazam for treating seizures associated with Dravet syndrome [NICE guidance].
• Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome [NICE guidance].
• Diabetic foot infections, antibacterial therapy: new guidance on management.
• Malaria, prophylaxis: updated country recommendations in the recommended regimens for prophylaxis against malaria in-line with Public Health England.
• Malaria, prophylaxis: updated guidance in-line with Public Health England recommendations.
• Mecasermin (Increlex®▼): risk of benign and malignant neoplasia [MHRA/CHM advice].
• Newborn life support image (see Life support algorithm image) updated.
• Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy [MHRA/CHM advice].
• Pneumococcal vaccine: updated guidance in-line with Public Health England recommendations.
• Sodium valproate: updated Pregnancy Prevention Programme [MHRA/CHM advice].
• Valproic acid: updated Pregnancy Prevention Programme [MHRA/CHM advice].
New Preparations: Zalkya® [ dienogest ].
For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes
This update contains 5 significant changes, 0 dose changes and 1 new preparation.
Significant Changes
New Preparations
For further details on changes in the BNFC click on
https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changesStockleys
This update contains 4 significant changes.
Significant Changes:
For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes
This update contains 5 significant changes, 2 new preparations, and 1 new monograph.
Significant Changes:
New Preparations: Takhzyro® [lanadelumab], Zinforo® [ceftaroline fosamil].
New Monographs: Cannabidiol.
For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes
